HealthQuill Peptides
Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations of the US-based company’s peptides for an upfront payment of $493 million.
Drugs Health Medical

Austria’s Cyprumed in $493 million pact with Merck to develop peptides

HQ Team April 17, 2025: Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations.

Read More
AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.
Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy 

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

Read More